IDEXX Labs upgraded by Cleveland Research
$IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Cleveland Research upgraded IDEXX Labs from Neutral to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2024 | $580.00 | Buy | BTIG Research |
| 1/30/2024 | $525.00 | Overweight → Neutral | Piper Sandler |
| 12/7/2023 | $602.00 | Outperform | Exane BNP Paribas |
| 12/4/2023 | Neutral → Buy | Cleveland Research | |
| 8/2/2023 | $610.00 | Overweight → Neutral | Atlantic Equities |
| 7/25/2022 | $415.00 | Buy → Hold | Stifel |
| 7/21/2022 | $530.00 → $435.00 | Neutral → Buy | Goldman |
| 7/12/2022 | $440.00 | Overweight | Piper Sandler |
Brian McKeon to Retire from IDEXX in June 2025 Andrew Emerson, Senior Vice President, Corporate and CAG Finance, to Serve as IDEXX's Next CFO IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group ("CAG") Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Company from March 1, 2025 until his retirement from IDEXX on June 1, 2025, to help ensure a
Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. Delivers EPS of $2.80, an increase of 11% as reported and 12% on a comparable basis, supported by operating margin expansion of 110 basis points as reported and 100 basis points on a comparable basis. Adjusts 2024 revenue guidance to $3,865 million - $3,890 million, a reduction of $38 million or ~1% at midpoint, incorporating expectations fo
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, October 31, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the l
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
SC 13G/A - IDEXX LABORATORIES INC /DE (0000874716) (Subject)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
8-K - IDEXX LABORATORIES INC /DE (0000874716) (Filer)
BTIG Research initiated coverage of IDEXX Labs with a rating of Buy and set a new price target of $580.00
Piper Sandler downgraded IDEXX Labs from Overweight to Neutral and set a new price target of $525.00
Exane BNP Paribas initiated coverage of IDEXX Labs with a rating of Outperform and set a new price target of $602.00
BRADENTON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Watch Restaurant Group, Inc. (NASDAQ:FWRG) ("First Watch" or the "Company"), the leading Daytime Dining concept serving breakfast, brunch and lunch, today announced the appointment of Irene Chang Britt to its Board of Directors, effective immediately. Ms. Chang Britt is an experienced independent board director and former Fortune 500 C-suite executive, who currently serves on the boards of established businesses and start-up companies representing a variety of industries, including retail, CPG, e-commerce and lifestyle. "We are thrilled to welcome Irene to the Board of Directors of First Watch, and I'm confident that our company wil
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. "We are excited to welcome Merilee to our Board of Directors," said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. "Merilee brings a wealth of operational, financial, and business experience to our team. Having started as employee #11 at IDEXX, she helped to drive a multitude of innovative growth strategies and successfully scaled the business from sta
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
4 - IDEXX LABORATORIES INC /DE (0000874716) (Issuer)
IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 20 years by 3.33% on an annualized basis producing an average annual return of 11.73%. Currently, IDEXX Laboratories has a market capitalization of $38.80 billion. Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 20 years ago, it would be worth $939.70 today based on a price of $469.85 for IDXX at the time of writing. IDEXX Laboratories's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's au
In the current market session, IDEXX Laboratories Inc. (NASDAQ:IDXX) price is at $487.60, after a 0.87% increase. However, over the past month, the stock fell by 3.66%, and in the past year, by 9.18%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. Comparing IDEXX Laboratories P/E Against Its Peers The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the com
IDEXX Laboratories's (NYSE:IDXX) short percent of float has risen 17.34% since its last report. The company recently reported that it has 2.05 million shares sold short, which is 3.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.44 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short int
Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. Delivers EPS of $2.80, an increase of 11% as reported and 12% on a comparable basis, supported by operating margin expansion of 110 basis points as reported and 100 basis points on a comparable basis. Adjusts 2024 revenue guidance to $3,865 million - $3,890 million, a reduction of $38 million or ~1% at midpoint, incorporating expectations fo
IDEXX Laboratories, Inc. (NASDAQ:IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 third quarter results for Thursday, October 31, 2024, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. EDT on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2024 Earnings Snapshot through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. ET on that day via the same link and will remain available for one year. The live call also will be accessible by telephone. To listen to the l
Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics recurring revenue growth of 6% as reported and 7% organic. Solid growth supported by continued benefits from IDEXX execution drivers, including record second quarter premium instrument placements and double-digit year-over-year global premium instrument installed base growth. Delivers EPS of $2.44, a decline of 9% as reported reflecting a $62 million, $0.56 per share discrete expense accrual related to an ongoing litigation matter. On a comparable basis, excluding this impact, EPS increased 15%. Updates 2024 revenue guidance to $3,885 million - $3,945 million, reflecting 6.2% -